Blizzy Code Presents Pfizer Update
- Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
- Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
- Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
- Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
- PFIZER REPORTS SECOND-QUARTER 2022 RESULTS
- Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™
- Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
- Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
- Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
- Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
- Valneva and Pfizer Announce Closing of Equity Investment
- Pfizer Declares Third-Quarter 2022 Dividend
- Truveta Announces Strategic Collaboration with Pfizer to Accelerate Safety Insights in Real Time
- Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
- Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
